Subsequently, discussions about the combinations of agents with distinct mechanisms of action (i.e., irreversible tyrosine kinase inhibitors (TKIs) or immune checkpoint inhibitors (ICIs)) have rapidly taken place to improve the therapeutic options of HER2-driven NSCLC. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.